Inegy

Simvastatin/Ezetimibe, the active ingredients in Inegy, are a HMG‑CoA reductase inhibitor and a cholesterol absorption inhibitor presented as oral tablets for oral use. They treat hypercholesterolemia and mixed dyslipidemia in adults, lowering elevated LDL‑cholesterol and total cholesterol levels to help reduce cardiovascular risk in patients with primary hyperlipidemia.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing, regulatory compliance across EU markets, and reliable logistics support.

Inegy combines simvastatin and ezetimibe to address lipid disorders by reducing cholesterol synthesis and absorption.

- Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: reduces both LDL‑cholesterol and triglycerides while modestly raising HDL‑cholesterol. - Primary hyperlipidemia: achieves target lipid profile when diet and lifestyle measures are insufficient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Gastrointestinal upset: includes nausea, abdominal discomfort, or diarrhea. - Myalgia: muscle aches without weakness, usually dose‑related. - Elevated liver enzymes: asymptomatic increase in ALT/AST. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with potential renal impairment. - Acute liver injury: marked elevation of hepatic transaminases, jaundice. - Severe allergic reactions: rash, pruritus, angioedema, or anaphylaxis. - Myopathy: muscle weakness with elevated CK levels. - Pancreatitis: rare inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, assess liver function and review patient history for muscle disorders. - Liver monitoring: obtain baseline ALT/AST and repeat periodically. - Muscle symptoms: discontinue if unexplained muscle pain, tenderness, or weakness occurs. - CYP3A4 inhibitors: avoid concomitant use with strong inhibitors such as itraconazole. - Pregnancy and lactation: safety not established; use only if potential benefit justifies risk. - Storage: Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Inegy may interact with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may raise simvastatin levels. - Gemfibrozil: increases risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates plasma concentrations of both components.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Fibrates (e.g., fenofibrate): modestly increase risk of muscle toxicity.